4.4 Article

Surveillance of adverse fetal effects of medications (SAFE-Med): Findings from the International Clearinghouse of Birth Defects Surveillance and Research

Journal

REPRODUCTIVE TOXICOLOGY
Volume 29, Issue 4, Pages 433-442

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.reprotox.2010.03.005

Keywords

Teratogen; Drug; Medication; Post-marketing surveillance; Birth defect; Preconception

Funding

  1. US Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities [U50/CCU207141, 1U50DD000524-01]
  2. INSERM (Institut National de la Sante et de la Recherche Medicale)
  3. DGS (Direction Generale de la Sante)
  4. InVS (Institut de Veille Sanitaire)
  5. CNPq/MS/DECIT [40.3444/2004-7, 40.1467/2004-0]
  6. CNPq, Brazil [472086/2004-9, 30.8885/2006-6]
  7. FAPERJ, Brazil [E-26/152.831/2006]
  8. Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT), Argentina [31101]
  9. CONICET: Argentina

Ask authors/readers for more resources

To evaluate whether the routinely collected data in birth defect registries could be used to assess association between medications and risk for congenital anomalies an exposed case-only design was performed. Twelve registries provided 18,131 cases exposed to a medication during the first trimester of pregnancy and with at least one major malformation. Odds ratios for malformations associated with maternal use of selected medications were computed. Among seven most commonly used medications very few significant associations with malformations were identified. Among fourteen potentially teratogenic medications several strong associations were found, including valproic acid with spina bifida, and insulin (as proxy for diabetes) with several types of cardiac defects. Finding known associations provides assurance on the validity of this approach, whereas identifying new associations provides a signal to be followed by confirmatory studies. Through this activity, international networks of birth defect registries can contribute with limited resources to post-marketing surveillance of the teratogenicity of medications. (C) 2010 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available